Serum Indices (HIL)
[Serum Indices (HIL)]
EPTIS Ringversuch Nr. 1616092 | Letze Änderung 2026-09-24 | URL: https://www.eptis.bam.de/pts1616092 https://www.eptis.bam.de/pts1616092
| Name des Anbieters | ||||||||||||||||||||||||||||
| Name des Anbieters | Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust | |||||||||||||||||||||||||||
| Ansässig in | United Kingdom | |||||||||||||||||||||||||||
| Sprache(n) | English | |||||||||||||||||||||||||||
| Anmerkungen | Provides EQA coverage for serum indices: haemolysis (H), icterus (I) and lipaemia (L), both for quantitive and category data. Analyte X is a unique element of the Scheme that looks at the impact of the HIL in the specimen on a particular analyte. The Scheme also collects and presents data on the current HIL cut-off that is in use by participating laboratories for Analyte X. The aim of this is to build up a library of the current variation in practice and provide laboratories with evidence of what they are doing compared to other users of the same method and other methods. Analyte X will change from distribution to distribution, please report in your usual units. Analyte X may be a Chemistry analyte or an Immunoassay analyte. | |||||||||||||||||||||||||||
| Klassifizierung | ||||||||||||||||||||||||||||
| Produktgruppen |
Health care / medical devices
|
|||||||||||||||||||||||||||
| Prüfgebiete |
Medical analysis
|
|||||||||||||||||||||||||||
| Technische Einzelheiten | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Ringversuchsziele | ||||||||||||||||||||||||||||
| Zielgruppe des Ringversuchs | Clinical Chemistry Public & Private Labs | |||||||||||||||||||||||||||
| Relevante Rechtsvorschriften oder Normen | ISO/IEC 17043:2023 | |||||||||||||||||||||||||||
| Weitere Ziele | Post market surveillance of testing methods | |||||||||||||||||||||||||||
| Teilnehmerzahl | ||||||||||||||||||||||||||||
| Anbieter unabhängig überprüft (akkreditiert, benannt, anerkannt) |
Akkreditiert durch UKAS auf der Grundlage von ISO/IEC 17043:2023 |
|||||||||||||||||||||||||||
| Die Durchführung des Ringversuchs ist in Auftrag gegeben durch | ||||||||||||||||||||||||||||
| Kosten | ||||||||||||||||||||||||||||
| Teilnahmegebühr | Contact provider for current fee, which depends on location and extent of service required. | |||||||||||||||||||||||||||
| Regelmässig durchgeführt | Ja (Monthly (11 per year)) | |||||||||||||||||||||||||||
| Der Ringversuch wird durchgeführt seit | 2015 | |||||||||||||||||||||||||||
| Kontaktdaten des Anbieters | ||||||||||||||||||||||||||||
| Anbieter | Kontaktperson | |||||||||||||||||||||||||||
|
Birmingham Quality (member of the UK NEQAS Consortium), University Hospitals Birmingham NHS Foundation Trust
Queen Elizabeth Medical Centre P O Box 3909 B15 2SQ Birmingham United Kingdom Telefon: +44 121 414 7300 Fax: Web: https://www.birminghamquality.org.uk https://www.birminghamquality.org.uk |
Birmingham Quality
Telefon: +44 121 414 7300 Fax: E-Mail: birminghamquality@uhb.nhs.uk birminghamquality@uhb.nhs.uk |
|||||||||||||||||||||||||||
Haben Sie einen Fehler entdeckt? Bitte wenden Sie sich an den zuständigen EPTIS Koordinator für United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.